Your session is about to expire
← Back to Search
CHANTIX (Varenicline) for Smoking Cessation after Acute Coronary Syndrome
Study Summary
This trial looks at the role of a nicotine antagonist in helping patients who have had a heart attack or other acute coronary syndrome to stop smoking.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 4 trial • 39 Patients • NCT04011280Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a recent heart problem and I do not smoke.I am a smoker and was admitted to the hospital for a heart attack.I am a smoker and was admitted to the hospital for a heart-related emergency.
- Group 1: sugar pill
- Group 2: active Chantix
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are being granted admittance to this experiment?
"Unfortunately, this clinical trial is currently not open for recruitment. It was initially posted on January 1st 2008 and last updated on July 26th 2010. If you are seeking alternative studies, there are presently 1502 trials recruiting individuals suffering from acute coronary syndrome as well as a further 26 medical experiments that utilise Varenicline 100 mg by mouth twice daily in the treatment of certain conditions."
Are there other trials that have gauged the efficacy of Varenicline 100 mg administered orally twice daily?
"Presently, 26 clinical trials for Varenicline 100 mg by mouth twice daily are in progress. Out of these studies, 4 have reached Phase 3 - the final stage before FDA approval. Although most of the research is taking place out of Charleston, South carolina, patients can find 69 locations where they can participate in this medical trial."
Has the FDA certified Varenicline 100 mg taken orally twice a day as safe?
"The safety rating for Varenicline 100 mg by mouth twice daily was awarded a score of 3 because this is an FDA-approved treatment and has gone through Phase 4 trial."
Are there still opportunities for people to participate in this research study?
"It appears that the clinical trial referred to has yet to commence recruitment, having first been posted in 2008 and last edited in 2010. However, as of now there are 1528 other trials actively admitting participants for research purposes."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger